Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Wagner

Showing results (311-320 of 355) with videos related to

Pageof 36
Sort By:
Journal of the National Cancer Institute|October 21, 2022
Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trialsMichael E Roth, Susan K Parsons, Patricia A Ganz, et al.
The Lancet. Oncology|September 1, 2020
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trialShaji K Kumar, Susanna J Jacobus, Adam D Cohen, et al.
BMC Cancer|October 24, 2025
The MyCancerGene study: a hybrid type 1 effectiveness-implementation randomized study comparing a patient-centered digital genetic health portal to usual care after receipt of cancer genetic testingDaniel Chavez-Yenter, Dominique Fetzer, Brian Egleston, et al.
Journal of Patient-Reported Outcomes|July 10, 2020
A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013Siu-Fun Wong, Joseph M Unger, James L Wade, et al.
JAMA Network Open|May 10, 2022
Association Between Surgery Preference and Receipt in Ductal Carcinoma In Situ After Breast Magnetic Resonance Imaging: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112)Soudabeh Fazeli, Bradley S Snyder, Ilana F Gareen, et al.
NEJM Evidence|March 13, 2023
Statins and Left Ventricular Ejection Fraction Following Doxorubicin TreatmentW Gregory Hundley, Ralph D'Agostino, Teresa Crotts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2020
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORxLynne I Wagner, Robert J Gray, Joseph A Sparano, et al.
JAMA Oncology|January 18, 2019
Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ TreatmentConstance D Lehman, Constantine Gatsonis, Justin Romanoff, et al.
JAMA Oncology|February 27, 2025
Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality: The ECOG-ACRIN EA9131 TrialAnand P Jillella, Sandra J Lee, Jessica K Altman, et al.
BMC Public Health|July 15, 2022
Study protocol for a hybrid type 1 effectiveness-implementation trial testing virtual tobacco treatment in oncology practices [Smokefree Support Study 2.0]Brett M Goshe, Autumn W Rasmussen, Lynne I Wagner, et al.
Pageof 36

Showing results (311-320 of 355) with videos related to

Sort By:
Pageof 36
Journal of the National Cancer Institute|October 21, 2022
Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trialsMichael E Roth, Susan K Parsons, Patricia A Ganz, et al.
The Lancet. Oncology|September 1, 2020
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trialShaji K Kumar, Susanna J Jacobus, Adam D Cohen, et al.
BMC Cancer|October 24, 2025
The MyCancerGene study: a hybrid type 1 effectiveness-implementation randomized study comparing a patient-centered digital genetic health portal to usual care after receipt of cancer genetic testingDaniel Chavez-Yenter, Dominique Fetzer, Brian Egleston, et al.
Journal of Patient-Reported Outcomes|July 10, 2020
A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013Siu-Fun Wong, Joseph M Unger, James L Wade, et al.
JAMA Network Open|May 10, 2022
Association Between Surgery Preference and Receipt in Ductal Carcinoma In Situ After Breast Magnetic Resonance Imaging: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112)Soudabeh Fazeli, Bradley S Snyder, Ilana F Gareen, et al.
NEJM Evidence|March 13, 2023
Statins and Left Ventricular Ejection Fraction Following Doxorubicin TreatmentW Gregory Hundley, Ralph D'Agostino, Teresa Crotts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2020
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORxLynne I Wagner, Robert J Gray, Joseph A Sparano, et al.
JAMA Oncology|January 18, 2019
Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ TreatmentConstance D Lehman, Constantine Gatsonis, Justin Romanoff, et al.
JAMA Oncology|February 27, 2025
Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality: The ECOG-ACRIN EA9131 TrialAnand P Jillella, Sandra J Lee, Jessica K Altman, et al.
BMC Public Health|July 15, 2022
Study protocol for a hybrid type 1 effectiveness-implementation trial testing virtual tobacco treatment in oncology practices [Smokefree Support Study 2.0]Brett M Goshe, Autumn W Rasmussen, Lynne I Wagner, et al.
Pageof 36